One in two patients ‘safely quit’ T2DM meds after bariatric surgery
Half of patients with morbid obesity and type 2 diabetes safely discontinue diabetes treatment within a year of bariatric surgery, Australian research suggests. Among patients…
Tag: Endocrinology – Diabetes
‘Limited’ semaglutide supplies on the way: TGA
Semaglutide will return to pharmacy shelves this month, but the TGA has warned not all patients previously prescribed the GLP-1 receptor agonist will be able…
‘Game-changing’ treatment gets green light for HFpEF
Leading cardiologist provides an update on the clinical management of heart failure with preserved ejection fraction
‘Overweight or psychotic’: Why this doctor kept prescribing semaglutide for obesity
“Patients need to worry about themselves, not other people’s conditions.” That is the view of Gold Coast psychiatrist Dr Manfred Penzhorn, who was prescribing semaglutide…
SGLT-2 inhibitors now first-line therapy for diabetes and CKD: new guidelines
Most patients with type 2 diabetes and chronic kidney disease should be managed with SGLT-2 inhibitors as first-line therapy in addition to lifestyle interventions, according…
Albuminuria in diabetic kidney disease ‘ups foot ulcer risk’
Patients with diabetic kidney disease are almost three times more likely to develop foot ulcers than those without renal complications, but only in the presence of…
Calls for aggressive control of semaglutide supply amid ongoing global shortage
Leading doctors have urged health authorities to aggressively control supply of semaglutide, including a potential emergency stockpile, as the global shortage of the drug drags…
TGA green-lights diabetes drug for HFpEF
Doctors can now prescribe empagliflozin to patients with symptomatic heart failure, regardless of left ventricular ejection fraction, in addition to standard therapy. Last month, the…
‘Promote semaglutide for weight loss and risk jail’: TGA
In its latest bid to solve the shortage of semaglutide (Ozempic), the TGA is threatening jail time and up to $1.1m in fines to social…
Diabetes drugs cut risk of severe COPD exacerbations: study
GLP-1 receptor agonists and SLGT-2 inhibitors cut the risk of exacerbations in patients with type 2 diabetes and COPD by about a third compared to…
